Preliminary work suggested that the β2-AR agonist isoproterenol could significantly promote the expression of PlexinA1 in gastric cancer cells and that PlexinA1 participates in the malignant progression of gastric cancer by mediating EMT and tumor angiogenesis in gastric cancer cells. Here, PLXNA1 is linked to neoplasm.